IN8bio, Inc. INAB
Set alert
As of Nov 2, 1:49 PM ET
- YTD
- -60.62%
- 1 year
- -52.74%
- Open
- 0.9277
- Prev close
- 0.9013
- Mkt cap
- 9.09M
- Vol
- 5.36K
- Avg vol
- 52.85K
- EPS
- -1.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9101
- High
- 1.00
- Forward P/E
- -0.80
- Beta
- -0.07
- Short ratio
- 0.51
- Inst. own
- 46.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.3045
- 200-d avg
- 0.70842
- 1y target
- 4.75
News
3 weeks ago globenewswire.com
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell…
1 month ago defenseworld.net
IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone
IN8bio (NASDAQ: INAB) outlined updates across its gamma-delta T-cell programs in autoimmune disease and oncology, including preclinical plans for its T-cell engager platform and clinical data in…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…
1 month ago globenewswire.com
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for…
1 month ago globenewswire.com
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for…
1 month ago globenewswire.com
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they…
-
2 months ago benzinga.com
IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per…
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came…
-
3 months ago benzinga.com
IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Journal Of Clinical Oncology
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients…
3 months ago globenewswire.com
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
5 months ago zacks.com
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate…
-
5 months ago benzinga.com
IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today…
5 months ago globenewswire.com
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs)…
5 months ago globenewswire.com
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).…
-
5 months ago benzinga.com
IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in…
-
5 months ago benzinga.com
IN8bio Q1 EPS $(0.26) Beats $(0.69) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.69) by 62.32 percent. This is a 87.96 percent increase over losses of $(2.16) per…
5 months ago globenewswire.com
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs.…
6 months ago globenewswire.com
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell…
7 months ago globenewswire.com
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and…
7 months ago defenseworld.net
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses…
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $6 price target.
7 months ago globenewswire.com
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant…
8 months ago globenewswire.com
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune…
-
8 months ago benzinga.com
IN8bio Promotes Kate Rochlin To President, COO, Effective Immediately
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the…
8 months ago globenewswire.com
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer…
9 months ago globenewswire.com
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune…
9 months ago globenewswire.com
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune…
10 months ago defenseworld.net
IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review
IN8bio (NASDAQ: INAB - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two…
10 months ago globenewswire.com
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio's novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
11 months ago benzinga.com
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
IN8bio, Inc. (the "Company") presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its…
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
Ohio State University Added As New Clinical Site In Ongoing Phase 1 Trial Of IN8bio's INB-100, Donor-Derived Allogeneic Gamma-Delta T Cell Therapy
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago benzinga.com
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark indices were mixed in premarket.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
2 years ago benzinga.com
Dow Falls Over 150 Points; General Motors Tops Q3 Views
Dow Falls Over 150 Points; General Motors Tops Q3 Views
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
2 years ago benzinga.com
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700…
-
2 years ago benzinga.com
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. ReShape…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
-
3 years ago benzinga.com
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders.